Uracyl spirooxetane nucleosides

Patent metadata

Field	Value
Publication number	US-9422323-B2
Application number	US-201314403587-A
Country	US
Kind code	B2
Filing date	May 24, 2013
Priority date	May 25, 2012
Publication date	Aug 23, 2016
Grant date	Aug 23, 2016

Abstract

The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R 9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.

First claim

The invention claimed is:

1. A compound of formula V:

or a pharmaceutically acceptable salt or solvate thereof.

Assignees

• Janssen Sciences Ireland Uc

Inventors

• Houpis Ioannis Nicolaos
• Jonckers Tim Hugo Maria
• Raboisson Pierre Jean-Marie Bernard
• Tahri Abdellah

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/7072

  having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine · CPC title

• C07H19/11 Primary

  containing cyclic phosphate · CPC title

• C07H19/10 Primary

  with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title